219 related articles for article (PubMed ID: 31082343)
1. [Ursodeoxycholic acid combined with bezafibrate in the treatment of refractory primary biliary cholangitis: a meta-analysis].
Feng BL; Yu HH; Shen W
Zhonghua Gan Zang Bing Za Zhi; 2019 Apr; 27(4):304-311. PubMed ID: 31082343
[No Abstract] [Full Text] [Related]
2. Bezafibrate for primary biliary cirrhosis.
Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2012 Jan; 1():CD009145. PubMed ID: 22259000
[TBL] [Abstract][Full Text] [Related]
3. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis.
Yin Q; Li J; Xia Y; Zhang R; Wang J; Lu W; Zhou Y; Zheng Y; Abudumijiti H; Chen R; Chen K; Li S; Liu T; Wang F; Lu J; Zhou Y; Guo C
Drug Des Devel Ther; 2015; 9():5407-19. PubMed ID: 26491252
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
Khakoo NS; Sultan S; Reynolds JM; Levy C
Dig Dis Sci; 2023 Apr; 68(4):1559-1573. PubMed ID: 36180756
[TBL] [Abstract][Full Text] [Related]
5. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
Takano K; Saeki C; Oikawa T; Hidaka A; Mizuno Y; Ishida J; Takakura K; Nakano M; Torisu Y; Amano K; Ishikawa T; Zeniya M; Tsubota A; Saruta M
J Gastroenterol Hepatol; 2020 Apr; 35(4):663-672. PubMed ID: 31677185
[TBL] [Abstract][Full Text] [Related]
6. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
Reig A; Sesé P; Parés A
Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
[TBL] [Abstract][Full Text] [Related]
7. Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis.
Lin W; Wang JX; Liu YJ
Syst Rev; 2024 Jan; 13(1):46. PubMed ID: 38287391
[TBL] [Abstract][Full Text] [Related]
8. Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA.
Tanaka A; Hirohara J; Nakanuma Y; Tsubouchi H; Takikawa H
J Gastroenterol; 2015 Jun; 50(6):675-82. PubMed ID: 25239675
[TBL] [Abstract][Full Text] [Related]
9. Fibrates for the treatment of pruritus in primary biliary cholangitis: a systematic review and meta-analysis.
Shen N; Pan J; Miao H; Zhang H; Xing L; Yu X
Ann Palliat Med; 2021 Jul; 10(7):7697-7705. PubMed ID: 34353058
[TBL] [Abstract][Full Text] [Related]
10. Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up.
Sorda JA; González Ballerga E; Barreyro FJ; Avagnina A; Carballo P; Paes de Lima A; Daruich J
Aliment Pharmacol Ther; 2021 Nov; 54(9):1202-1212. PubMed ID: 34587309
[TBL] [Abstract][Full Text] [Related]
11. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid.
Takeuchi Y; Ikeda F; Fujioka S; Takaki T; Osawa T; Yasunaka T; Miyake Y; Takaki A; Iwasaki Y; Kobashi H; Yamamoto K; Itoshima T
J Gastroenterol Hepatol; 2011 Sep; 26(9):1395-401. PubMed ID: 21443659
[TBL] [Abstract][Full Text] [Related]
12. Additional fibrate treatment in UDCA-refractory PBC patients.
Chung SW; Lee JH; Kim MA; Leem G; Kim SW; Chang Y; Lee HY; Yoon JS; Park JY; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH
Liver Int; 2019 Sep; 39(9):1776-1785. PubMed ID: 31162879
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis.
Zhang H; Li S; Feng Y; Zhang Q; Xie B
Clin Exp Med; 2023 Sep; 23(5):1741-1749. PubMed ID: 36318376
[TBL] [Abstract][Full Text] [Related]
14. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
Honda A; Ikegami T; Nakamuta M; Miyazaki T; Iwamoto J; Hirayama T; Saito Y; Takikawa H; Imawari M; Matsuzaki Y
Hepatology; 2013 May; 57(5):1931-41. PubMed ID: 22911624
[TBL] [Abstract][Full Text] [Related]
15. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.
Hazzan R; Tur-Kaspa R
J Clin Gastroenterol; 2010; 44(5):371-3. PubMed ID: 19881358
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis: A meta-analysis.
Wang ZL; Song KM; Jin R; Xie YD; Wang YQ; Liu ZC; Feng B
Medicine (Baltimore); 2022 Mar; 101(9):e28987. PubMed ID: 35244071
[TBL] [Abstract][Full Text] [Related]
17. Bezafibrate treatment: a new medical approach for PBC patients?
Kanda T; Yokosuka O; Imazeki F; Saisho H
J Gastroenterol; 2003; 38(6):573-8. PubMed ID: 12825134
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid for primary biliary cirrhosis.
Gong Y; Huang ZB; Christensen E; Gluud C
Cochrane Database Syst Rev; 2008 Jul; (3):CD000551. PubMed ID: 18677775
[TBL] [Abstract][Full Text] [Related]
19. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid.
Lens S; Leoz M; Nazal L; Bruguera M; Parés A
Liver Int; 2014 Feb; 34(2):197-203. PubMed ID: 23998489
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis.
Zhang Y; Li S; He L; Wang F; Chen K; Li J; Liu T; Zheng Y; Wang J; Lu W; Zhou Y; Yin Q; Xia Y; Zhou Y; Lu J; Guo C
Drug Des Devel Ther; 2015; 9():2757-66. PubMed ID: 26045661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
